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Abstract: Lower urinary tract symptoms (LUTS) associated with benign prostatic   hyperplasia 
(BPH) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS 
associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the 
α1-adrenergic receptor antagonists. Silodosin is a new α1-adrenergic receptor antagonist that 
is selective for the α1A-adrenergic receptor. By antagonizing α1A-adrenergic receptors in the 
prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since 
silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor, 
it minimizes the propensity for blood pressure-related adverse effects caused by α1B-adrenergic 
receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 
8 mg exhibited significant improvements in the International Prostate Symptom Score and maxi-
mum urinary flow rate compared with those receiving placebo. Silodosin showed early onset 
of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin 
was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported 
adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel 
selective α1A-adrenergic receptor antagonist, was effective in general and without obtrusive side 
effects. This review provides clear evidence in support of the clinical usefulness of silodosin in 
the treatment of LUTS associated with BPH.
Keywords: α1A-adrenoceptor antagonist, silodosin, selective, benign prostatic hyperplasia, 
lower urinary tract symptoms
Benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a common progressive disease among men, with 
an incidence that is age-dependent. Histological BPH, which typically develops after 
the age of 40 years, ranges in prevalence from .50% at 60 years to as high as 90% 
by 85 years of age.1–3 BPH contributes to, but is not the single cause of, bothersome 
lower urinary tract symptoms (LUTS) that may affect quality of life. The prevalence 
of troublesome symptoms increases with age, with symptoms typically occurring in 
men aged $50 years.3
Histologically, BPH is characterized by a progressive increase in the number 
of epithelial and stromal cells, that develops initially in the periurethral area of the 
prostate gland.1,4,5 This cellular proliferative process increases prostatic smooth 
muscle tone, resulting in urethral constriction.6 Benign prostatic enlargement may 
also result from the proliferation of epithelial and stromal cells, and may further 
contribute to constriction of the urethra, leading to bladder outlet obstruction. Benign 
prostatic enlargement and bladder outlet obstruction do not occur in all men with Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  histopathological BPH/LUTS, and the presence of benign 
prostatic enlargement does not necessarily mean that bladder 
outlet obstruction will develop.5
Approximately 50% of patients with histological BPH 
report moderate to severe LUTS,2 consisting of storage and 
voiding symptoms.2,3 Commonly reported storage-related 
symptoms include urinary frequency, urgency, and nocturia. 
Voiding symptoms, typically attributable to urethral obstruc-
tion, consist of decreased and intermittent force of the urinary 
stream and the sensation of incomplete bladder emptying.1 
Although bothersome LUTS may affect quality of life by 
altering normal daily activities and sleep patterns, mortality 
associated with BPH is rare.1,7 Although uncommon, serious 
complications of BPH may occur, including acute urinary 
retention, renal insufficiency, urinary tract infections, hema-
turia, bladder stones, and renal failure.6,8 These complications 
may be triggered or worsened by inadequate management of 
BPH. The incidence of acute urinary retention in untreated 
patients ranges from 0.3% to 3.5% per year; the risk of devel-
oping other long-term complications is unclear.8
The management of patients with BPH includes non-
pharmacological, pharmacological, and surgical options, 
with the choice of therapy typically depending on the 
presence and severity of symptoms.1,9 Watchful waiting is 
the preferred management strategy for patients with mild 
LUTS and those who do not perceive their symptoms to 
be particularly bothersome. Pharmacological treatments 
include α1-adrenergic receptor antagonists (or blockers) 
and 5α-reductase inhibitors, which are recommended for 
use alone or in combination in patients with bothersome 
moderate to severe LUTS. Currently, adrenergic receptor 
antagonists are commonly used as the first-line treatments 
for LUTS associated with BPH.3,6
α1-Adrenergic receptors
Adrenergic receptors were originally divided into α-adrenergic 
receptor and β-adrenergic receptor categories,8 but applica-
tion of molecular biological methods has confirmed 
nine adrenergic receptor subtypes: α1A (formerly named 
α1C), α1B, α1D, α2A, α2B, α2C, β1, β2, and β3.10–12 All three 
α1-adrenergic receptor subtypes exist in a wide range of   
human tissues.13,14
In terms of male LUTS, α1-adrenergic receptor expres-
sion in the prostate, urethra, spinal cord, and bladder is 
important. Molecular and contraction studies in human 
prostate tissue demonstrate that the α1A-adrenergic receptor 
subtype predominates (70%–100%) in prostate stroma.15,16 
Because baseline tone is present in prostate smooth muscle 
(due to its rich sympathetic innervation), blockade of   prostate 
  α1A-adrenergic receptors results in relaxation of prostate 
smooth muscles. Hence, α1-adrenergic receptor blockade is 
capable of modifying the dynamic (prostate smooth muscle 
contraction) component in BPH. Another tissue important 
in LUTS is the urethra. To date, most studies show that 
all regions of the human urethra (including bladder neck 
and intraprostatic urethra) mainly contain α1A-adrenergic 
receptors.17,18
α1-Adrenergic receptor antagonists also mediate vaso-
dilation in the vasculature; therefore, one of the side effects 
of treating LUTS with α1-adrenergic receptor antagonists is 
hypotension. Although the main α1-adrenergic receptor sub-
type in the large vasculature is the α1B-adrenergic receptors, 
α1A-adrenergic receptors predominate in human splanchnic 
(mesenteric, splenic, hepatic, and distal omental) resistance 
arteries.19 Interestingly, α1-adrenergic receptor expression 
increases two-fold in representative (mammary) arteries 
with aging, with the ratio of α1B:α1A increasing, whereas no 
alteration occurs in veins.19 Studies of pharmacy databases 
in Europe suggest that the administration of α1-adrenergic 
receptor blockers increases the incidence of hip fractures 
(chosen as a surrogate for clinically important orthostatic 
hypotension).20 Further analysis with regard to the precise 
α1-adrenergic receptor antagonists prescribed suggests that 
avoidance of α1B-adrenergic receptor blockade may result in 
fewer overall hip fractures.3
Molecular and pharmacological 
characteristics of silodosin
A number of α1-adrenergic receptor antagonists (alfuzosin, 
doxazosin, tamsulosin, terazosin, naftopidil) have been 
approved for the treatment of BPH worldwide. The earlier 
α1-adrenergic receptor antagonists cause vasodilatory symp-
toms, including postural hypotension and dizziness, and have 
to be used carefully in patients, especially in older patients suf-
fering from dysuria. Tamsulosin has relative selectivity for the   
α1A-adrenergic receptor. However, in patients with BPH-
related LUTS, it has long been desired to develop a thera-
peutic agent having a selective suppressive action on urethral 
contractions, with less hypotension, including postural 
hypotension. This effect may be minimized by use of agents 
that selectively antagonize the α1A-adrenergic receptor.7 At 
the start of the 1990s, Kissei Pharmaceutical Co Ltd began 
development of α1-adrenergic receptor antagonists that were 
highly selective for the lower urinary tract without affecting 
blood pressure,21,22 and this led to the discovery of silodosin, 
a novel indoline derivative.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Receptor-binding studies (saturation and replacement 
experiments) were performed using membrane fractions 
prepared from mouse-derived LM (tk-) cells expressing 
human α1A-, α1B-, or α1D-adrenergic receptor and 3H-prazosin 
hydrochloride, to study the affinity of silodosin for human 
α1-adrenergic receptor subtypes. As indicated in Table 1,23 
the affinity of silodosin for the α1A-adrenergic receptor was 
162 times higher than that for the α1B-adrenergic receptor, 
and was 55 times higher than that for the α1D-adrenergic 
receptor (calculated as a ratio of 162/2.95), having the highest 
selectivity for the α1A-adrenergic receptor among the tested 
α1-adrenergic receptor antagonists.
The study was designed to determine the native tis-
sue selectivity and α1-adrenoceptor subtype selectivity of 
silodosin by performing functional studies on contraction 
of isolated muscular preparations from the rabbit and the 
rat. Tissue samples of α1A-adrenergic receptor-rich prostate, 
urethra, and bladder trigone isolated from male Japanese 
white rabbits, α1B-adrenergic receptor-rich spleen iso-
lated from male Sprague Dawley rats, and α1D-adrenergic 
receptor-rich thoracic aorta also isolated from male Sprague 
Dawley rats were used to study the suppression of nora-
drenaline-induced contraction in a muscle bath by silo-
dosin, tamsulosin hydrochloride, naftopidil, and prazosin 
hydrochloride. All of the tested α1-adrenergic receptor 
antagonists shifted the noradrenaline dose-response curves 
for the rabbit prostate, rat spleen, and rat thoracic aorta 
to the right in a concentration-dependent manner.23,24 The 
antagonistic action of silodosin against noradrenaline-
induced contraction of each isolated tissue was compared 
with that of α1-adrenergic receptor antagonists by the pA2 
or pKb value (Table 2).23 Silodosin was about 280 times 
more selective for prostate tissue than for splenic tissue and 
about 50 times more selective than for thoracic aortic tissue, 
which shows that silodosin is significantly more selective for 
prostate tissue compared with other α1-adrenergic receptor 
antagonists. Furthermore, the selectivity for the urethra and 
bladder trigone was found to be comparable with that for the 
prostate. The selectivity of tamsulosin hydrochloride for the 
prostate was about 20 times higher than that of selectivity 
for spleen, but comparable with that for the thoracic aorta. 
On the other hand, naftopidil and prazosin hydrochloride 
were more selective for the spleen and thoracic aorta (0.4 
and 5 times for naftopidil and 25 and 20 times for prazosin 
hydrochloride, respectively), showing the selectivity for the 
prostate to be lower.
To evaluate in vivo uroselectivity (ratio of reactivities for 
lower urinary tract against blood pressure), several studies25,26 
were performed, using rats. Intravenous dosing of phenyleph-
rine, an α1-adrenergic receptor agonist, through the femoral 
vein increases intraurethral pressure in urethane-anesthetized 
male Sprague-Dawley rats. This effect should be blocked by 
α1-adrenergic receptor antagonists (Table 3).25 The results 
showed that each of the α1-adrenergic receptor antagonists 
dose-dependently suppressed the phenylephrine-induced 
increase in intraurethral pressure, lowering the mean blood 
pressure. Silodosin potently suppressed the phenylephrine-
induced increase in intraurethral pressure, but tamsulosin 
hydrochloride equally suppressed the phenylephrine-induced 
increase in intraurethral pressure and also decreased the mean 
blood pressure at a similar dose. Naftopidil and prazosin 
hydrochloride showed a greater ability to decrease mean 
blood pressure in contrast with silodosin. Heart rate was 
decreased by about 10% by naftopidil at doses of 1000 µg/
kg and 3000 µg/kg. No other antagonist had this effect. Effi-
cacy in suppressing the phenylephrine-induced intraurethral 
pressure increase, defined by the ID50 value, was decreased 
by tamsulosin hydrochloride, silodosin, prazosin hydro-
chloride, and naftopidil (in descending order), and efficacy 
in decreasing mean blood pressure, defined by the ED15 
value, decreased in order of prazosin hydrochloride, tamsu-
losin hydrochloride, silodosin, and naftopidil, showing that 
Table 1 Affinity and selectivity for human α1-AR subtype for silodosin and other α1-AR antagonists
Compound Ki value (nmol/L) α1-AR subtype selectivitya
α1A-AR α1B-AR α1D-AR α1A/α1B ratio α1D/α1B ratio
Silodosin 0.039 ± 0.006 6.5 ± 0.6 2.2 ± 0.1 162 2.95
Tamsulosin hydrochloride 0.012 ± 0.002 0.12 ± 0.00 0.030 ± 0.005 9.55 3.80
Naftopidil 23 ± 7 7.8 ± 0.0 4.4 ± 0.4 0.372 1.78
Prazosin hydrochloride 0.12 ± 0.01 0.028 ± 0.002 0.078 ± 0.007 0.204 0.316
wB4101 hydrochloride 0.17 ± 0.01 1.1 ± 0.1 0.22 ± 0.04 6.03 5.01
BMY7378 dihydrochloride 75 ± 21 28 ± 7 0.43 ± 0.06 0.389 64.6
Notes: The Ki value in the table presents the mean ± standard error of 3 experiments. The subtype selectivity (α1A/α1B and α1D/α1B ratios) was calculated from the ratio after 
converting the concentration, specifically, using 10M [M = pKi (α1A or α1D) – pKi (α1B)].
Reproduced with permission from Yakugaku Zasshi vol 126 Special issue. Copyright © 2006 Pharmaceutical Society of Japan.23Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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silodosin (ED15/ID50) has the highest selectivity for the lower 
urinary tract at 11.7, followed by tamsulosin hydrochloride, 
prazosin hydrochloride, and naftopidil in this order.25
Clinical efficacy and safety
Four Phase III studies conducted in Japan,27 the US,28 and 
Europe29 have evaluated the use of silodosin in the treatment 
of patients with BPH. The main efficacy results are sum-
marized in Table 4.
The first randomized, double-blind, placebo-controlled 
Phase III study was conducted at 88 centers in Japan.27 The 
men included were aged $50 years, were outpatients, and 
had LUTS associated with BPH, the latter diagnosed on 
a digital rectal examination or ultrasonographic findings. 
Inclusion criteria were a total International Prostate Symptom 
Score (IPSS) $8, an associated quality of life score of $3, 
prostate volume (measured by transabdominal or transrectal 
ultrasonography) $20 mL, a maximum urinary flow rate 
(Qmax) ,15 mL/sec with a voided volume $100 mL, and a 
residual urine volume ,100 mL.
After completing a seven-day “washout” and a seven-day, 
single-blind, placebo runin period, patients were randomized 
to receive oral silodosin 4 mg twice daily, tamsulosin 0.2 mg/
day, or placebo twice daily for 12 weeks. This study was 
performed as a double-dummy design. Drugs were prescribed 
as follows: silodosin group (silodosin 4 mg twice a day, tam-
sulosin placebo twice a day); tamsulosin group (tamsulosin 
0.2 mg once a day in the morning, tamsulosin placebo once 
a day, silodosin placebo twice a day), and placebo group 
(silodosin placebo twice a day, tamsulosin placebo twice 
a day).
At the end of the washout period and at weeks 1, 2, 4, 
8 and 12 during the treatment period, subjective symptoms 
(IPSS and quality of life scores) and medication compliance 
were recorded, and uroflowmetry and physical examination 
(blood pressure and heart rate) conducted. Clinical laboratory 
tests were conducted at the start of the observation period and 
at four and 12 weeks of treatment. All adverse events were 
recorded and assessed for severity and causal relationship 
with the investigational product.
The primary endpoint for evaluation of efficacy was 
change in total IPSS from baseline; secondary endpoints were 
change in Qmax and evaluation of subjective symptoms, eg, 
IPSS voiding and storage scores and quality of life score.
In total, 457 patients were enrolled and randomized to 
receive silodosin (n = 176), tamsulosin (n = 192), or placebo 
(n = 89). One patient in the silodosin group was excluded 
from the full analysis set due to protocol violation. There 
Table 2 pA2 or pKb values of silodosin and other α1-AR antagonists for noradrenaline-induced contraction in the isolated rabbit 
prostate, urethra and bladder, and in the isolated rat spleen and thoracic aorta
Compound pA2 or pKbvalues
α1A-AR α1B-AR α1D-AR
Prostatea Urethraa Bladder trigonea Spleenb Thoracic aortab
Silodosin 9.60 ± 0.05c 8.71 ± 0.09  
(0.98 ± 0.32)
9.35 ± 0.15c 7.15 ± 0.05  
(0.67 ± 0.09*)
7.88 ± 0.05  
(1.00 ± 0.18)
Tamsulosin  
hydrochloride
9.93 ± 0.07c 9.00 ± 0.06  
(1.16 ± 0.27)
9.48 ± 0.14c 8.64 ± 0.06  
(0.61 ± 0.18*)
9.82 ± 0.06  
(0.91 ± 0.20)
Naftopidil 6.69 ± 0.05c  
(1.13 ± 0.21)
6.48 ± 0.11  
(0.93 ± 0.39)
6.80 ± 0.07  
(0.91 ± 0.25)
6.30 ± 0.07  
(0.69 ± 0.23)
7.48 ± 0.06  
(1.14 ± 0.23)
Prazosin  
hydrochloride
7.91 ± 0.02  
(1.08 ± 0.09)
7.96 ± 0.04  
(0.85 ± 0.13*)
8.10 ± 0.05  
(0.97 ± 0.18)
9.34 ± 0.13  
(0.56 ± 0.26*)
9.17 ± 0.06  
(1.11 ± 0.23)
Notes: each value in the table presents mean ± standard error of 4–5 animals. each value in a parenthesis presents the slop of the Schild plot. a) Rabbits, b) Rats, c) pK; bvalue. 
*Significantly different from the unity at P , 0.05 by paired-t test. 
Abbreviations: pA2, negative logarithmic value of molar concentration of antagonistic blockers necessary to parallel shift 2 times the independent stimulant 
concentration-reaction curve to the higher concentration side; pKb value, negative logarithmic value of dissociation constant for binding of antagonistic blockers to 
receptors.
Reproduced with permission from Yakugaku Zasshi vol 126 Special issue. Copyright © 2006 Pharmaceutical Society of Japan.23
Table 3 ID50 value, eD15 value and uroselectivity of silodosin and 
other α1-AR antagonists after intravenous administration in the 
anesthetized rat
Drug IUP MBP Uroselectivity
ID50 (µg/kg) ED15 (µg/kg) (ED15/ID50)
Silodosin 0.932 10.9 11.7
Tamsulosin  
hydrochloride
0.400 0.895 2.24
Naftopidil 361 48.1 0.133
Prazosin  
hydrochloride
4.04 0.792 0.196
Notes: ID50 value (the dose to suppress IUP increase by 50%); eD15 value (the dose 
to decrease the MBP by 15%).
Reproduced with permission from Yakugaku Zasshi vol 126 Special issue. Copyright 
© 2006 Pharmaceutical Society of Japan.25Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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were no significant differences among the three groups in 
baseline characteristics, except for the quality of life score. 
Therefore, an adjusted analysis by baseline quality of life 
score was used for the primary endpoint.
The primary outcome measure, ie, change in total IPSS 
from baseline, was −8.3 ± 6.4, −6.8 ± 5.7, and −5.3 ± 6.7 in the 
silodosin, tamsulosin, and placebo groups, respectively. There 
were significantly greater decreases with silodosin than placebo 
from one week after starting treatment. In the early-stage com-
parison, silodosin elicited a significantly larger decrease in IPSS 
than did tamsulosin at two weeks. The mean (95% confidence 
interval [CI]) intergroup differences in the total IPSS between 
silodosin and placebo, and between silodosin and tamsulosin, 
were −3.0 (−4.6, −1.3) and −1.4 (−2.7, −0.2), respectively, 
thus confirming that silodosin was better than placebo and not 
inferior to tamsulosin (both P , 0.001). Figure 1 shows the 
time course of change in total IPSS score in this randomized, 
placebo-controlled, double-blind Phase III study.27
Silodosin was significantly better than placebo in terms 
of quality of life score (P , 0.002). Voiding symptoms 
(as measured by components of the total IPSS) were sig-
nificantly improved in the silodosin group compared with 
the tamsulosin and placebo groups.21 The mean ± standard 
deviation [SD] changes from baseline in IPSS subscores 
were −5.8 ± 4.6, −4.8 ± 4.1, and −3.8 ± 4.8 in the silodosin, 
tamsulosin, and placebo groups, respectively (P = 0.023, 
silodosin versus tamsulosin; P , 0.001, silodosin versus 
placebo). Mean changes from baseline in storage symptoms 
were −2.5 ± 2.9, −2.1 ± 2.6, and −1.5 ± 2.6 in the respective 
groups (P , 0.006, silodosin versus placebo; silodosin versus 
0
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Figure  1  Time  course  of  change  in  International  Prostate  Symptom  Score  in 
randomized, placebo-controlled, double-blind Phase III study.
Copyright © 2006, John wiley and Sons. Reproduced with permissions from Kawabe 
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Table 4 Results of pivotal Phase III clinical trials
Study Patients (n) Baseline Change Baseline Change
IPSS, mean (SD) Qmax, mean (SD), mL/sec
Kawabe et al27
  Silodosin 8 mg/day 175 17.1 (5.7) −8.3 (6.4)* 9.88 (2.75) 1.70 (3.31)
  Tamsulosin 0.2 mg/day 192 17.0 (5.7) −6.8 (5.7) 9.41 (2.81) 2.60 (3.98)
  Placebo 89 17.1 (6.1) −5.3 (6.7) 0.18 (2.72) 0.26 (2.21)
Marks et al28 (Pooled US studies)
  Silodosin 8 mg/day 466 21.3 (5.1) −6.4 (6.63)* 8.7 (2.60) 2.6 (4.43)*
  Placebo 457 21.3 (4.9) −3.5 (5.84) 8.9 (2.80) 1.5 (4.36)
Chapple et al29 (ITT population)
  Silodosin 8 mg/day 371 19(4) −7.0: −2.3 [−3.2, −1.4]* 10.78 (n = 381) 3.77
  Tamsulosin 0.4 mg/day 376 19 (4) −6.7: −2.0 [−2.9. −1.1]* 10.27 (n = 384) 3.53
  Placebo 185 19 (4) −4.7 10.32 (n = 190) 2.93
IPSS voiding symptoms, mean (SD) IPSS storage symptoms, mean (SD)
Kawabe et al27
  Silodosin 8 mg/day 175 10.8 (4.1) −5.8 (4.6)* 6.4 (3.0) −2.5 (2.9)*
  Tamsulosin 0.2 mg/day 192 10.8 (4.2) −4.8 (4.1) 6.2 (2.9) −2.1 (2.6)
  Placebo 89 10.9 (4.4) −3.8 (4.8) 6.3 (2.8) −1.5 (2.6)
Marks et al28 (Pooled US studies)
  Silodosin 8 mg/day 466 12 (3.6) −4.0 (4.31)* 9.3 (2.6) −2.3 (2.93)*
  Placebo 457 12 (3.5) −2.1 (3.76) 9.3 (2.5) −1.4 (2.99)
Chapple et al29
  Silodosin 8 mg/day 381 11.3 (3.13) −4.5: −1.7: [−2.2, −1.1]* 7.9 (2.49) −2.5: −0.7 [−1.1, −0.2]*
  Tamsulosin 0.4 mg/day 384 11.0 (3.27) −4.2: −1.4 [−2.0, −0.8]* 7.9 (2.51) −2.4: −0.6 [−1.1, −0.2]*
  Placebo 190 11.3 (3.22) −4.7 8.0 (2.64) −1.8
Note: *Significant difference versus placebo.
Abbreviations: IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; SD, standard deviation; ITT, intention to treat; [95% CI: confidence interval] Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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tamsulosin, not significant). In addition to significant effects 
in patients with moderate symptoms (IPSS 8–19), silodosin 
also showed significant improvements in total IPSS over 
placebo in patients with severe symptoms (IPSS $ 20).
All three groups had improvements from baseline in 
Qmax at week 12, and there were no significant differences in 
the change in Qmax between groups.21 It is known that Qmax 
depends on the voided volume at measurement. Therefore, 
the change in Qmax was compared among the three treatment 
groups in the subgroup of patients with a change in voided 
volume of , 50% before and after treatment. In this analy-
sis, the improvement in Qmax from baseline was significantly 
greater in the silodosin group compared with the placebo 
group (P = 0.005), with mean ± SD changes from baseline 
of 1.70 ± 3.31, 2.60 ± 3.98, and 0.26 ± 2.21 mL/sec in the 
silodosin, tamsulosin, and placebo groups, respectively.
The incidence of adverse events was 88.6%, 82.3%, and 
71.6% in the silodosin, tamsulosin, and placebo groups, respec-
tively. Intergroup comparisons showed that adverse events 
were significantly (P , 0.001) more frequent in the silodosin 
group than in the placebo group. The incidence rates of drug-
related adverse events were 69.7%, 47.4%, and 36.4% in the 
three groups, respectively, showing a significantly (P , 0.001) 
higher frequency of adverse events in the silodosin group than 
in the placebo and tamsulosin groups. Adverse events result-
ing in withdrawal occurred in 18 (10.2%), 11 (5.7%), and 
four (4.5%) patients in the silodosin, tamsulosin, and placebo 
groups, respectively. All of these adverse events resolved after 
discontinuing treatment. The most common adverse event in 
the silodosin group was abnormal ejaculation, which occurred 
in 39 patients (22.3%) compared with three (1.6%) in the 
tamsulosin group and none in the placebo group. However, 
only five men (2.9%) discontinued treatment due to abnormal 
ejaculation. Other adverse events occurring in the silodosin 
group at a frequency .5% and more frequently than in the pla-
cebo group included upper respiratory tract infection (18.9% 
silodosin, 27.6% tamsulosin, and 0% placebo), thirst (10.3%, 
3.6%, and 4.5%, respectively), loose stool (9.1%, 3.6%, and 
5.6%), diarrhea (6.9%, 6.8%, and 5.6%), urinary incontinence 
(6.3%, 5.7%, and 0%), and dizziness (5.1%, 7.3%, and 4.5%). 
There were no clinically significant differences in systolic/
diastolic blood pressure or heart rate between the silodosin and 
tamsulosin groups. In addition, the incidence of side effects 
relating to hypotension (such as dizziness) for silodosin was 
similar to that for tamsulosin and placebo.
The efficacy and safety of long-term administration of 
silodosin in patients with LUTS associated with BPH was 
investigated in a 52-week, open-label, oral administration 
study in 361 outpatients aged 50 years or older (mean 
age 67.3 ± 6.7 years) with a total IPSS score $8, qual-
ity of life score $3, prostate volume $20 mL, voiding 
  volume $100 mL, and Qmax #15 mL/sec at this time point.30 
Silodosin 4 mg (reduced to 2 mg when an adverse event 
occurred) was administered twice daily after breakfast and 
dinner. This study was not an open-label extension of the 
pivotal Phase III study, but a stand-alone open-label study.
The study results showed that the total IPSS score was 
18.4 ± 6.3 at baseline, 13.1 ± 6.3 at week 4, 10.6 ± 6.0 at 
week 12, 9.4 ± 6.1 at week 28, and 8.2 ± 5.7 at week 52, 
demonstrating a benefit over 52 weeks beginning at week 4. 
For the IPSS subscores, the score for voiding symptoms was 
10.9 ± 4.5 at baseline, 7.5 ± 4.5 at week 4, and 4.4 ± 3.9 at 
week 52, and for storage symptoms, 7.5 ± 3.2 at baseline, 
5.6 ± 2.9 at week 4, and 3.8 ± 2.4 at week 52, demonstrating 
sustained improvement from as early as week 4 (P = 0.000). 
Additionally, the IPSS subscores for residual sensation, 
intermittency of urination, urinary stream, straining urination, 
pollakisuria, urinary urgency, and nocturia similarly lasted 
for 52 weeks from as early as week 4 (P = 0.000).
The quality of life score of all patients administered 
silodosin was 4.8 ± 0.9 at baseline, and 3.7 ± 1.3 at week 4, 
3.3 ± 1.3 at week 12, 3.0 ± 1.4 at week 28, and 2.7 ± 1.3 at 
week 52, also showing that the improvement in quality of life 
lasted for 52 weeks from as early as week 4 (P = 0.000).
The Qmax was 9.51 ±  3.09  mL/sec  at  baseline, 
11.35 ± 4.68 mL/sec at week 4, 10.57 ± 4.68 mL/sec at week 
12, 11.07 ± 4.69 mL/sec at week 28, and 12.36 ± 5.74 mL/sec at 
week 52, also showing improved efficacy lasting over 52 weeks 
and starting as early as week 4. In addition, the residual urine 
volume was 44.5 ± 61.1 mL at baseline and 30.2 ± 39.2 mL at 
week 52, again showing improvement (P = 0.000).
Two US clinical studies that evaluated the efficacy 
and tolerability of silodosin 8 mg once daily in men with 
BPH are described individually, and were pooled and 
reported by Marks et al.28 Both were 12-week, multicenter, 
randomized, double-blind, placebo-controlled trials. The 
two studies enrolled patients aged $50 years who had an 
IPSS $13, a Qmax 4–15 mL/sec, and a postvoid residual   
volume ,250 mL. The studies began with a four-week 
placebo runin period; patients with a .30% decrease in 
IPSS or a .3 mL/sec increase in Qmax at the end of this 
period were excluded from subsequent randomization. The 
enrolled men showed an average IPSS score of 21.2–21.4 
points and a Qmax of 8.4–9.0 mL/sec. After treatment, the 
IPSS improvements were 6.3 and 6.5 points versus 3.4 and 
3.6 points in the placebo arms, respectively, and the flow Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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rate improvements were 2.2 and 2.9 mL/sec versus 1.2 and 
1.9 mL/sec, respectively. Furthermore, the pooled data from 
the two trials were evaluated by Marks et al in their assess-
ment of the efficacy and safety of silodosin for treatment of 
LUTS and BPH. Of 923 patients (mean age 65 years), 466 
received silodosin and 457 received placebo. After 0.5 weeks 
(range 3–4 days) of treatment, patients receiving silodosin 
versus placebo achieved significant improvement in total 
IPSS (difference −1.9, P , 0.0001), and storage (−0.5, 
P , 0.0002) and voiding (−1.4, P , 0.0001) subscores. The 
mean ± SD change from baseline in total IPSS was −4.2 ± 5.3 
for silodosin versus −2.3 ± 4.4 for placebo. Differences 
(silodosin versus placebo) in IPSS and subscores increased 
by week 12 (P , 0.0001). Mean change from baseline in 
Qmax 2–6 hours after the initial dose was greater (P , 0.0001) 
with silodosin (2.8 ± 3.4) than with placebo (1.5 ± 3.8). Dif-
ferences remained significant (P , 0.001) through week 12. 
The most common treatment-emergent adverse event was 
mild retrograde ejaculation (silodosin 28.1% of patients, 
placebo 0.9%). Few patients treated with silodosin (2.8%) 
discontinued because of retrograde ejaculation. Proportions 
of patients with treatment-emergent orthostatic hypotension 
were similar for silodosin (2.6%) and placebo (1.5%).
The report suggested that significant changes were 
observed at the earliest postbaseline assessments. IPSS, 
including storage and voiding subscores, improved signifi-
cantly (P , 0.0005) within 3–4 days. Moreover, significant 
improvement (P , 0.0001) in Qmax was observed 2–6 hours 
after the first dose of silodosin. Silodosin was safe and well 
tolerated. Retrograde ejaculation was the most common drug-
related adverse event but rarely resulted in discontinuation 
of treatment. In addition, silodosin had a low incidence of 
orthostatic hypotension, and was associated with few events 
of dizziness. The rapid onset of clinical efficacy established 
for silodosin would make it a useful option for the treatment 
of patients with signs and symptoms of BPH. A long-term 
open-label extension study of patients from these two US 
studies was also conducted over 40 weeks, with all patients 
receiving silodosin 8 mg once daily. 31
In Europe, a new multicenter double-blind, placebo-
controlled and active-controlled parallel-group clinical 
study was conducted in 72 hospital clinics and inpatient 
units in 11 countries.29 After a washout phase of 14 days 
and a four-week, single-blind, placebo runin period, subjects 
who met the selection criteria were randomly assigned (in a 
ratio of 2:2:1) to a 12-week treatment with silodosin 8 mg, 
tamsulosin 0.4 mg, or placebo, administered once daily. Men 
aged 50 years and over with LUTS (defined by a stable total 
IPSS score $13), bladder outlet obstruction (defined by Qmax 
4–15 mL/sec and a minimum voided volume of 125 mL).
A total of 1228 patients were screened, 955 of whom were 
randomized to receive silodosin 8 mg (n = 381),   tamsulosin 
0.4 mg (n = 384), or placebo (n = 190). The study   investigated 
whether silodosin was noninferior to tamsulosin and superior 
to placebo. The first endpoint was evaluation of IPSS; the 
secondary ones were urinary storage and voiding symptoms, 
quality of life, and Qmax. Treatment responders were defined 
as those having a 25% decrease in IPSS and a 30% increase 
in Qmax from baseline. In the primary endpoints, superiority 
of silodosin and tamsulosin treatments versus placebo was 
observed, with highly statistically significant differences 
at all weeks (P , 0.001) both in the intention-to-treat (dif-
ference from placebo, −2.3 and −2.0, respectively) and per 
protocol populations (difference from placebo, −2.2 and −1.9, 
respectively). In all three treatment groups, the percentage 
of IPSS responders progressively increased from baseline 
to week 12. At study end, 66.8% and 65.4% of the patients 
receiving silodosin or tamsulosin, respectively, were respond-
ers compared with 50.8% in the placebo group. The differ-
ences versus placebo were highly significant (P , 0.001) for 
both active compounds, whereas the comparison between 
silodosin and tamsulosin did not show a statistically signifi-
cant difference. The same results as previous studies were 
obtained from the analysis of urinary storage and voiding 
symptoms, when compared with placebo. Only for nocturia 
did silodosin have an advantage over tamsulosin, but this 
was not statistically significant (P = 0.095 for tamsulosin 
and the placebo, P = 0.314 for silodosin versus tamsulosin, 
and P = 0.013 for silodosin versus placebo). However, there 
was no significant difference in Qmax (responders 46.6% 
silodosin, 46.5% tamsulosin, and 40.5% placebo; responders 
had reduction .30% from baseline) between the two active 
drugs and placebo. There was also no difference between 
the two drugs for the quality of life parameter, whereas both 
were better than for placebo. The adverse events for the three 
groups were 34.9% for silodosin, 28.9% for tamsulosin, and 
24.2% for placebo, and disturbances in ejaculatory function 
were significantly greater in the group treated with silodosin 
(14.2%) than in those treated with tamsulosin (2.1%) or 
placebo (1.1%). When analyzing cardiovascular adverse 
events, no statistically significant differences were found in 
laboratory parameters, vital signs, and electrocardiograms 
for silodosin and tamsulosin when compared with placebo. 
There were significant greater variations in blood pressure 
and heart rate for silodosin than for tamsulosin when com-
pared with placebo.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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The urodynamic effects of silodosin were assessed in two 
Japanese studies employing invasive pressure flow measure-
ments. Yamanishi et al32 treated 36 patients with LUTS and 
BPH and performed pressure flow studies at baseline and 
at three months, noting a decrease in detrusor pressure at 
maximal flow (pdet Qmax) from 80.6 to 48.6 cm H2O and a 
decrease in the bladder outlet obstruction index from 70.2 to 
32.6 (P , 0.0001 for both). In a similar study, Matsukawa 
et al33 treated 57 patients aged 51–84 (mean 68.5) years 
with a prostate volume of 25–120 mL (mean 42.0 mL) with 
silodosin 8 mg for four weeks, and performed pressure flow 
studies before and after. Total IPSS and IPSS quality of life 
scores were significantly improved after drug administration. 
On free uroflowmetry, Qmax and postvoid residual volume 
were significantly improved without a significant change in 
voided volume. Bladder volume at first desire to void signifi-
cantly increased, but maximum cystometric capacity showed 
no significant change. Uninhibited detrusor contraction was 
observed in 24 patients (42.1%) before silodosin administra-
tion. After drug administration, 14 of the 24 patients (58.3%) 
had apparent improvement in detrusor overactivity, and 
uninhibited detrusor contraction disappeared in six patients 
(25%). In eight patients (33.3%) in whom uninhibited detru-
sor contraction amplitude showed a remarkable decrease of 
greater than 15 cm H2O, the mean amplitude of uninhibited 
detrusor contraction decreased from 51.6 to 11.5 cm H2O. 
None of the 33 patients who were free from uninhibited 
detrusor contraction before administration showed unin-
hibited contraction upon testing after administration. Qmax 
and postvoid residual volume significantly improved after 
silodosin administration, similar to findings on free uro-
flowmetry. After administration, Pdet Qmax significantly 
decreased from 72.5 to 51.4 cm H2O for a mean decrease 
of 21.1 cm H2O. Mean bladder outlet obstruction index sig-
nificantly decreased from 60.6 to 33.8 after administration 
(P , 0.0001). These findings suggest the possibility that 
the highly selective effect on the α1A receptor at the bladder 
neck might be responsible for the observed reduction in 
obstruction, which is nearly commensurate with the effect 
of surgical intervention.
The efficacy and safety of silodosin and tamsulosin in 
patients with LUTS/BPH were also evaluated by a ran-
domized crossover method.34 BPH patients with IPSS $8, 
quality of life score $3, prostate volume $20 mL, void 
volume $100 mL, and Qmax ,15 mL/sec were included, 
and were randomly divided into two groups, ie, a silodosin 
group (four weeks of twice-daily administration of silodosin 
4 mg, followed by four weeks of once-daily administration 
of tamsulosin 0.2 mg) or a tamsulosin-preceding group 
(four weeks’ administration of tamsulosin followed by four 
weeks’ administration of silodosin). Forty-six patients were 
assigned to the silodosin-preceding group and 51 patients 
to the tamsulosin-preceding group. In the first treatment 
period, both drugs significantly improved the total IPSS 
score, but the improvement on silodosin was significantly 
superior to that on tamsulosin. After crossover treatment, 
significant improvement was observed only with silodosin 
treatment. Moreover, intergroup comparison of changes 
revealed that silodosin showed significant improvement of 
straining and nocturia with first and crossover treatments, 
respectively, compared with tamsulosin. Silodosin also 
significantly improved quality of life score in both treatment 
periods, while tamsulosin significantly improved quality of 
life score only in the first treatment period. Adverse drug 
reactions were observed in 16 of 97 patients (16.5%) after 
administration of silodosin and in two of 97 patients (2.1%) 
after administration of tamsulosin. The most frequent 
adverse drug reaction was ejaculatory disorder with silo-
dosin in seven patients (7.2%). However, the incidence of 
dizziness with silodosin was similar to that with tamsulosin. 
The authors concluded that silodosin exhibits excellent effi-
cacy in improving subjective symptoms in both initial and 
crossover treatment, and it appears to improve the quality 
of life of patients with BPH/LUTS.
Table 5 Adverse effects of silodosin compared with tamsulosin 
and placebo
Adverse effects Silodosin (%) Tamsulosin (%) Placebo (%)
ejaculatory  
disorders
14.2–28.1 1.6–2.1 0–1.1
(Retrograde  
ejaculation)
Upper respiratory  
tract infection
18.9 27.6 19.1
Thirst 10.3 3.6 4.5
Loose stool 9.1 3.6 5.6
Urinary  
incontinence
6.3 5.7 0
Diarrhea 2.6–6.9 6.8 5.6
Dizziness 3.2–5.1 7.3 4.5
Orthostatic  
hypotension
2.6 – 1.5
Headache 2.4–5.5 2.9 0.9–4.7
Discontinued the  
study due to TeAe
2.1–10.7 1.0–5.7 1.6–4.5
Discontinued the  
study due to
1.3–2.9 0.3 0
ejaculatory  
disordersClinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Safety profile
Despite its high uroselectivity, silodosin is associated with 
side effects (summarized in Table 5). As described previ-
ously, the most commonly reported adverse reactions in the 
Phase III studies27–29 were ejaculatory disorders, including 
retrograde ejaculation (22.3%, 28.1%, and 14.2%, respec-
tively, compared with 1.6% and 2.1% with tamsulosin 
and 0%–1.1% with placebo). This adverse event was the   
main cause of discontinuation of silodosin (2.8%, 2.9%, and 
1.3%, respectively). The ejaculatory disorders are the result 
of smooth muscle relaxation in the prostate, urethra, blad-
der neck, and vas deferens.35,36 The α1A-adrenergic receptor 
is mainly expressed in the bladder neck, vas deferens, and 
seminal vesicles.37 Thereby, this adverse reaction is explained 
by the high α1A-adrenergic receptor subtype selectivity of 
silodosin. Relaxation of the prostate, urethra, and bladder 
neck might cause retrograde ejaculation.
In addition, nonclinical studies have shown that 
α-adrenergic receptors, particularly α1A-adrenergic recep-
tors, are essential for the physiological contraction of the 
vas deferens and hence for sperm delivery from the testes 
to the urethra.38 Reduced ejaculation is caused by impaired 
function of the vas deferens rather than by alterations in 
sperm formation, number, or function.35 This effect does 
not represent a safety concern because it indicates only a 
reduction in semen volume, which is reversible (within a 
few days) upon discontinuation of treatment,36,39 and is not 
perceived as particularly bothersome (discontinuation rates 
due to ejaculation disorders in patients treated with silodosin 
were very low in the Phase III studies).
Silodosin for treatment of BPH symptoms was analyzed 
by two Phase III studies from the US to examine the relation-
ship between treatment efficacy and occurrence of abnormal 
ejaculation.40 Silodosin-treated patients were stratified by the 
absence or presence of retrograde ejaculation. Groups were 
compared using analysis of covariance (for change from 
baseline) and responder analyses. Of 466 patients receiving 
silodosin, 131 (28%) reported retrograde ejaculation and 335 
(72%) did not; four of the 457 patients receiving placebo 
(0.9%) reported retrograde ejaculation. Most retrograde 
ejaculation events in silodosin-treated patients (110/134, 
82%) were reported as “orgasm with absence of seminal 
emission”. Silodosin-treated patients with and without 
retrograde ejaculation showed significant improvement in 
IPSS, Qmax, and quality of life versus placebo (P , 0.02). 
Patients with retrograde ejaculation versus patients without 
retrograde ejaculation experienced numerically greater 
improvement, but differences were not statistically significant 
(P . 0.05). For patients with retrograde ejaculation, the odds 
of achieving improvement of $3 in IPSS and $3 mL/sec 
in Qmax by study end were 1.75 times those for patients 
without retrograde ejaculation (P = 0.0127). Absence of 
seminal emission may predict superior treatment efficacy of 
silodosin in individual patients. A similar study was reported 
from Japan.41 The silodosin-treated group with ejaculation 
disorder (SIL + EjD) showed larger change in total IPSS 
than the silodosin subgroup without ejaculation disorder 
(SIL − EjD, difference −4.36 [95% CI −6.44, −2.27]) and 
the placebo group (difference −6.29 [95% CI −8.44, −4.14]). 
Remarkable improvement was observed at all time points. 
The success rate in SIL + EjD was higher than in SIL − EjD 
and placebo when measured using a 25% reduction in the 
total IPSS category. There were no significant differences in 
adverse drug reaction rates other than for ejaculation disorder. 
Discontinuation rates between SIL + EjD and SIL − EjD were 
similar. The authors suggest that ejaculation disorder caused 
by selective α1A-adrenergic receptor antagonists is associated 
with very large improvements in LUTS. Patients with ejacula-
tion disorder may have greater symptomatic improvements 
without incremental risk for adverse events.
The other adverse events commonly associated with silo-
dosin were upper respiratory tract infection (18.9% versus 
27.6% and 19.1% with tamsulosin and placebo, respectively), 
thirst (10.3% versus 3.6% and 4.5%), loose stools (9.1% ver-
sus 3.6% and 5.6%), urinary incontinence (6.3% versus 5.7% 
and 0%), diarrhea (2.6%–6.9% versus 6.8% and 5.6%), diz-
ziness (3.2%–5.1% versus 7.3% and 4.5%), and orthostatic 
hypotension (2.6% versus 1.5% for placebo).27–29
In a 52-week, long-term study in Japan,30 the cumula-
tive incidences of adverse drug reactions extrapolated by 
the Kaplan–Meier method were 61.0% and 67.7% at weeks 
28 and 52, respectively, indicating that more adverse drug 
reactions developed earlier, although delayed-type adverse 
drug reactions were not observed.
The percentage of patients who discontinued treatment 
because of adverse drug reactions and abnormal clinical 
laboratory values was 12.1% (44/364 patients) and 0.6% 
(2/360 patients), respectively. Adverse drug reactions which 
led to study discontinuation in at least three patients included 
ejaculation disorder in 15 patients, diarrhea in four patients, 
and light-headed feeling in three patients. The percentage 
of patients whose dose was reduced to 4 mg/day because of 
adverse drug reactions was 11.8% (43/364), and dose reduc-
tion due to abnormal clinical laboratory test values occurred 
in 0.3% of patients (1/360). Of these adverse drug reactions, 
ejaculation disorder disappeared in three of 17 patients, Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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dizziness on standing up in eight of 10 patients, thirst in four 
of six patients, light-headed feeling in four of six patients, and 
nasal congestion in two of five patients during the adminis-
tration period. Of 91 patients who had ejaculation disorder, 
five could not be evaluated for resolution of symptoms due 
to lack of sexual activity and in two patients who underwent 
transurethral resection of prostate after completion of treat-
ment, but was confirmed in 73 patients after completion of 
administration and in 11 patients during administration.
Cardiovascular vital signs were recorded for any evidence 
of a cardiovascular effect. The systolic blood pressure was 
137.5 ± 18.1 mmHg at baseline, 134.7 ± 17.9 mmHg at 
week 28, and 134.6 ± 18.8 mmHg at week 52. The dia-
stolic blood pressure was 80.1 ± 11.8 mmHg at baseline, 
78.4 ± 12.0 mmHg at week 28, and 78.9 ± 12.1 mmHg at 
week 52; the pulse rate was 72.3 ± 11.4 beats/min at baseline, 
72.8 ± 11.8 beats/min at week 28, and 74.3 ± 12.3 beats/min 
at week 52, showing only a little change in measurements, 
and not raising clinical concerns.
These study results demonstrated that silodosin improved 
urinary function and LUTS associated with BPH starting 
soon after the first administration, without causing delayed 
adverse drug reactions or loss of efficacy, and confirmed that 
efficacy was sustained over the course of the study.
An open-label extension study was performed by Marks 
et al in the US.31 The primary objective of this study was 
to assess safety. Of the 661 participants, 435 (65.8%) 
completed the study and 431 (65.2%) experienced 924 
adverse events. No serious adverse events occurred that 
the investigators considered to be drug-related. Adverse 
events reported most often included retrograde ejaculation 
(20.9% of patients), diarrhea (4.1%), and nasopharyngitis 
(3.6%). Orthostatic hypotension and dizziness occurred in 
2.6% and 2.9% of patients, respectively. The percentage of 
patients with treatment-emergent adverse events, stratified 
by preceding double-blind treatment (placebo or silodosin), 
was higher for de novo (previous treatment with placebo 
71.5%) than for continuing silodosin treatment (58.3%). 
More patients receiving de novo (7.5%) versus continuing 
treatment (1.9%) discontinued study participation because 
of retrograde ejaculation. The mean ± SD IPSS change 
from baseline (after 12 weeks of previous double-blind 
therapy) to week 40 (observed cases) was −4.5 ± 6.7 for de 
novo treatment (P , 0.0001) and −1.6 ± 6.0 for continuing 
treatment (P , 0.01). Silodosin was well tolerated and in 
particular was associated with low incidences of dizziness 
and orthostatic hypotension. During this extension study, 
no cardiac disorders and no prolongation of corrected QT 
interval were found with long-term use of silodosin.   Another 
study42 also showed that co-administration of silodosin and 
phosphodiesterase-5 inhibitors (sildenafil or tadalafil) in 
healthy men caused no important orthostatic changes in blood 
pressure or heart rate.
Intraoperative floppy iris syndrome is a complication 
of cataract surgery observed in patients who have been 
previously treated with α1-blockers, mainly tamsulosin. 
The   clinical manifestations of intraoperative floppy iris 
syndrome are pupil constriction, fluttering, and billowing of 
the iris stroma, with a propensity of the iris to prolapse dur-
ing cataract surgery.42 A prospective study was conducted 
in 1968 Japanese patients receiving various α1-blockers, 
including silodosin, before cataract surgery.43 The over-
all incidence of intraoperative floppy iris syndrome was 
1.1% and, interestingly, no intraoperative cases occurred 
in patients receiving silodosin. However, one case of 
intraoperative floppy iris syndrome has been reported in 
a nine-month, open-label, tolerability study of silodosin.44 
It is recommended that patients with BPH/LUTS being 
considered for cataract surgery be questioned to ascertain 
whether they have taken α1-adrenergic receptor antago-
nists. If so, the ophthalmologist should be prepared for 
possible modifications to their surgical technique should 
intraoperative floppy iris syndrome be observed during 
the procedure.
Conclusion
α1-Adrenergic receptor antagonists remain a mainstay in the 
treatment of male LUTS and clinical BPH. Silodosin, a new 
α1A-adrenergic receptor antagonist, is now used worldwide. 
Clinical studies have shown that this selective α1A-adrenergic 
receptor antagonist is very attractive and more effective than 
placebo for both voiding and storage symptoms, as well 
as improving measures of quality of life in LUTS arising 
from BPH. Silodosin has excellent early efficacy, and is at 
least as effective as other α1-blockers. Silodosin shows a 
strong effect not only on symptoms but also on obstruction 
as measured by pressure flow studies, a finding perhaps 
explained by its strong selectivity for the α1A-adrenergic 
receptor. Although, silodosin is a very attractive drug, fur-
ther studies for efficacy and safety, especially, a long-term 
study comparing this drug with other α1-adrenergic receptor 
antagonists, are needed.
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